Health Canada Confirms G7-First Status After Apotex Generic Nod

Two Generics Approved, Seven Under Review

The Apotex authorization arrived just days after Health Canada cleared the first generic semaglutide injection on April 28, 2026, manufactured by Dr. Reddy's Laboratories of India [Source: canada.ca/en/health-canada/news/2026/04/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide.html]. With the Apotex decision, Health Canada says seven additional generic semaglutide submissions from different companies remain under active review [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html].

The department stated it expects to make further regulatory decisions on those submissions "in the coming weeks and months" [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html]. Both authorized generics are indicated for the once-weekly treatment of adult patients with type 2 diabetes to manage blood sugar levels [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html].

Apotex Targets Pharmacy Shelves Within Weeks

Catherine Thomas, Apotex's vice president of global communications, told CBC News by email that the new Apotex product should be available to Canadians within weeks [Source: cbc.ca/news/health/ozempic-semaglutide-generic-version-canada-9.7184915]. "Our team is committed to bringing this product to market in the very near future," Thomas said. "Our goal is to have it available in the coming weeks" [Source: cbc.ca/news/health/ozempic-semaglutide-generic-version-canada-9.7184915].

Thomas added that Apotex is working with insurance companies to secure coverage, noting that "for most private plans, the process to include generics happens shortly after launch" [Source: cbc.ca/news/health/ozempic-semaglutide-generic-version-canada-9.7184915]. Patients can monitor coverage status through the insurance coverage checker.

How Pricing Could Move

Under the pan-Canadian Pharmaceutical Alliance pricing structure, the first generic medication could cost 75 to 85 per cent of the brand name price [Source: cbc.ca/news/health/ozempic-semaglutide-generic-version-canada-9.7184915]. Once a second product enters the market, the price for both drops to 50 per cent of the brand price, and with three or more generics available the cost would decrease to about 35 per cent of brand-name Ozempic's price [Source: cbc.ca/news/health/ozempic-semaglutide-generic-version-canada-9.7184915].

According to Felix, a Canadian integrated health-care platform cited by Global News, the average cost of Ozempic injections can range between $200 and $450 per month depending on the province [Source: globalnews.ca/news/11826332/canada-approves-2nd-generic-version-semaglutide]. Current pharmacy prices tracked on GLP1Prices.ca place Ozempic between $222 and $663 per month across Canadian pharmacies, indicating the upper end of real-world prices runs higher than the Felix figure.

Health Canada has stated that many generic medications are 45 to 90 per cent cheaper than brand name versions [Source: globalnews.ca/news/11826332/canada-approves-2nd-generic-version-semaglutide]. Dana Small, a neurology and neurosurgery professor at McGill University, told Global News that estimated post-generic prices she has heard are "anywhere from like $40 to $80" [Source: globalnews.ca/news/11826332/canada-approves-2nd-generic-version-semaglutide].

Equivalence and Oversight

Health Canada described generic semaglutide as a complex synthetic product that is pharmaceutically equivalent to the brand name biologic drug, and said its review ensures differences between products do not affect safety, efficacy, or quality [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html]. The agency said it will continue to monitor authorized generic semaglutide products and take action if any unexpected concerns arise [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html].

Dr. Hertzel Gerstein, a professor in the medicine department at McMaster University and a diabetes physician, told Global News that "when Health Canada approves a generic version of a drug, they go through a very rigorous process and ensure that the drug that they're approving is as close to the original drug chemically as it can possibly be" [Source: globalnews.ca/news/11826332/canada-approves-2nd-generic-version-semaglutide].

What Comes Next

With seven submissions still pending and the patent landscape now open, the pace of further approvals will determine how quickly the PCPA's tiered pricing thresholds activate. The remaining brand-name semaglutide products in Canada include Wegovy and Rybelsus, while the tirzepatide products Mounjaro and Zepbound remain off-patent timelines distinct from semaglutide. Readers can follow approval activity on the generic semaglutide tracker or consult the FAQ for additional context.